Share your experience and insights to help guide the design of cutting- edge nanorobot technology for Pancreatic cancer detection and treatment.

Pancare Foundation is inviting expressions of interest from patients or carers who have experience with pancreatic cancer to join a Pancare-led Pancreatic Cancer Consumer Reference Group. Consumer perspectives into this research project will help guide the design of a cutting-edge nanorobot technology aimed at detecting pancreatic cancer early and monitoring treatment responses.

About the project

The project is supported by the Australian Government via the Cooperative Research Centres Projects grant and is delivered in partnership between the Pancare Foundation, NanoCube Health Pty Ltd, RMIT University, BNNT Technology Limited, The University of Melbourne and Ouroborus Pty Ltd. The project began in early 2025 and is scheduled to finish by the end of 2027.

The nanorobotic technology is in early pre-clinical stages of development. Throughout the project, the nanorobotic technology will undergo prototype testing and validations, with ambitions of progressing to clinical development in the future.

What will the Consumer Reference Group do?

The Consumer Reference Group will share their valuable experience and insights, as patients or carer for a loved one, to guide the design of this nanorobotic technology. This ensures the technology reflects what matters most to patients, carers and families.

We anticipate the time commitment for the initiative will be up to four hours on a quarterly basis, with some additional onboarding and training at the start of the project in July-August 2025. Meetings (including meetings with the scientists developing the technology) will be held online, approximately quarterly from mid-2025 to December 2027. Remunerations will be provided to show our appreciation for your valuable time and contributions. 

Who are we looking for?

Pancare aims to select members of the Pancreatic Cancer Consumer Reference Group by end June 2025 and where possible will aim to balance the membership of the Group across different domains, including, but not limited to: geographic regions, patients and carers, gender and cultural backgrounds.

Please note: as the nanorobotic technology is in early, pre-clinical development, there are no immediate clinical benefits from participation. However, your involvement will help influence future advances in early detection and treatment monitoring.

Interested in joining?

If you are interested in being considered for the Consumer Reference Group, please complete this EOI template by the end of Thursday 19th June 2025.

We will review all submissions and aim to update you of the outcome by late June.

For further information

Please feel free to contact us if you have any questions:

• Nonie Chan  [email protected]
• Mark Buzza  [email protected]